Assessment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patient's Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Therapeutic Use
- Sponsors AbbVie
- 07 Jun 2017 Biomarkers information updated
- 29 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 10 May 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.